Blog

The International Criminal Court issued arrest warrants on Thursday for Israeli Prime Minister Benjamin Netanyahu, his former defense minister and Hamas officials, accusing them of war crimes and crimes against humanity over the war in Gaza and the October 2023 attacks that triggered Israel's offensive in the Palestinian territory.The decision turns Netanyahu and the others into internationally wanted suspects and is likely to further isolate them and complicate efforts to negotiate a cease-fire to end the 13-month conflict. But its practical implications could be limited since Israel and its major ally, the United States, are not members of the court and several of the Hamas officials have been subsequently killed in the conflict.Netanyahu and other Israeli leaders have condemned ICC Chie...

Arrest warrants have been issued for Israeli Prime Minister Benjamin Netanyahu and former defence secretary Yoav Gallant by the International Criminal Court (ICC).The warrants are for alleged war crimes and crimes against humanity related to the war in Gaza that Israel launched following the 7 October attacks by Hamas. The prime minister's office said the warrants against him and Gallant were "anti-semitic" and said Israel "rejects with disgust the absurd and false actions".Another warrant was issued for the arrest of Hamas leader Mohammed Diab Ibrahim al Masri for war crimes and crimes against humanity.Al Masri, also known as Mohammed Deif, was the mastermind behind the 7 October attacks.It is unclear if he is still alive, following an airstrike that Israel claimed killed him earlier this...

Here are Thursday's biggest calls on Wall Street: Goldman Sachs reiterates Nvidia as buy The firm raised its price target on the stock to $165 per share from $150 following earnings. "We reiterate our Buy rating on NVDA (which is also on the Americas Conviction List) and highlight the rich catalyst path ahead." Morgan Stanley initiates UMB Financial as overweight Morgan Stanley said the commercial bank has a "differentiated deposit base." "We see UMBF as one of the best ways to play lower rates among the Midcap Banks." Rosenblatt upgrades Palo Alto Networks to buy from neutral The firm upgraded the stock following Palo Alto earnings on Wednesday. "The company delivered another strong quarterly performance, driven by successful execution of its platform strategy." William Blair downgrades U...

Goldman Sachs sees big gains ahead for Merus on the back of the company's cancer treatment. The firm initiated coverage of the cancer therapeutics stock with a buy rating on Wednesday, alongside a $73 per share price target. Goldman's forecast implies 68% upside from Wednesday's close. Goldman Sachs analyst Richard Law highlighted the company's estimated glomerular filtration rate (EGFR) petosemtamab antibody, which is intended for treating recurring and metastatic head and neck squamous cell carcinoma. Law said the antibody has already shown promising results and can be a key growth driver for the stock moving forward. MRUS YTD mountain Merus stock. "We believe peto has a reasonable chance of demonstrating best-in-class efficacy/safety profile," Law said. "While some ADCs [antibody-drug c...